Canada-based oral drug delivery firm IntelGenx is set to initiate a Phase IIa clinical trial of Montelukast VersaFilm in the first quarter of next year for patients with Alzheimer’s disease (AD).
The move follows Health Canada’s clearance for the firm’s clinical trial application to treat mild-to-moderate AD.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Montelukast was originally approved in 1997 by the US Food and Drug Administration (FDA) to treat asthma and seasonal allergic rhinitis.
The firm is currently working towards re-formulating the medicine into an oral film-based therapeutic for treating neurodegenerative diseases.
According to IntelGenx, Montelukast VersaFilm has various advantages such as a decrease in first-pass-effects, easy administration, low dosing and toxicity and improved compliance, compared to tablets.
The randomised, double-blind, placebo-controlled proof-of-concept Phase IIa trial is planned to include around 70 patients at eight sites in Canada.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPrimary objectives of the trial are safety, feasibility, tolerability, and efficacy of Montelukast buccal film after daily dosing for 26 weeks.
IntelGenx president and CEO Dr Horst Zerbe said: “There are limited treatments available for AD and, of those that are approved, none are disease modifying.
“We are very excited to commence this trial and evaluate the potential of Montelukast as a much-needed treatment for AD patients.”
An oral film formulation of Montelukast is reported to have been safe and tolerable during a Phase I trial in healthy participants.
Montelukast further demonstrated 52% higher bioavailability, when compared with the regular Montelukast tablet, and was observed to cross the blood-brain barrier.
